Thierry Jahan, MD

Lung cancer specialist

Dr. Thierry M. Jahan specializes in the treatment of lung cancer, mesothelioma, sarcomas and endocrine tumors and the use of multiple treatments. In addition to caring for patients, Jahan is involved in studying new treatments for malignancies related to the chest. His research focuses on treatments for the management of lung cancer and malignant mesothelioma.

Jahan earned a medical degree from George Washington University in Washington, D.C. He completed an internship, residency and fellowship in medicine at Cedars Sinai Medical Center in Los Angeles and then completed a fellowship in hematology and oncology at UCSF, before joining the faculty in 1994. He is the recipient of the Medical Housestaff Outstanding Teacher Award at UCSF Medical Center at Mount Zion. He also is member of numerous professional societies, including the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer and the Association of Northern California Oncologists. He is a clinical professor of medicine at UCSF.


Thoracic Surgery and Oncology
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 885-3882
Fax: (415) 353-7151

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Academic Title


More about Thierry Jahan

Additional Languages



George Washington University 1987


Cedars-Sinai Los Angeles, Internal Medicine 1990


UCSF, Hematology/Oncology 1994

Selected Research and Publications

  1. Kindler HL, Ismaila N, Armato SG, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jan 18; JCO2017766394.
  2. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 Jan; 19(1):58-64.
  3. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10; 35(11):1231-1239.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.